About Aurigene

G V Prasad is the Co-chairman and Managing Director of Dr. Reddy’s Laboratories Ltd. He is widely credited as the architect of Dr. Reddy’s successful global generics strategy. He envisioned new business platforms such as the custom pharmaceutical services business and specialty pharmaceuticals, and is dedicated to building the innovation side of the business. He is also a champion of sustainability thinking. Prasad earned his degree in Chemical Engineering from the Illinois Institute of Technology, Chicago (USA) in 1982 and his Masters in Industrial Administration from Purdue University (USA) in 1983.

Satish Reddy is the Chairman of Dr. Reddy’s Laboratories. He joined the company in 1993 and since then, has held positions of increasing responsibility. Satish led the organization’s transition from a uni-focused manufacturer of APIs (active pharmaceutical ingredients) to a company that moved up the value-chain with a diverse product portfolio of finished dosage formulations. He oversaw the expansion and establishment of a strong footprint for Dr. Reddy’s finished dosage products in Russia, CIS countries, and other emerging markets.

Satish holds a degree in Chemical Engineering from Osmania University (India), and an MS in Medicinal Chemistry from Purdue University (USA), where he received the 2009 Distinguished Alumnus Award from the School of Pharmacy and Pharmaceutical Sciences.

Parag Agarwal is the Chief Financial Officer of Dr. Reddy’s Laboratories Limited. He joined Dr. Reddy’s from London-based Reckitt Benckiser PLC, where he was the CFO for Health. In a career spanning over 33 years, Parag has held several leadership positions, contributing significantly to the financial performance of his organizations. With over 10 years of working experience in several countries outside India, he brings deep global experience in leading business and financial strategy, transforming finance function, as well as in M&A strategy and execution.

He has expertise in driving performance management of investments, financial result delivery, and driving operating margin improvement through revenue and cost optimization across the value chain. Parag has held leadership positions in diverse cultural contexts and has driven large-scale change management programs in ambiguous and dynamic environments. Prior to his nine-year stint at Reckitt, Parag was associated with organizations such as Unilever, GSK Consumer Healthcare, and Genpact. Parag is a Chartered Accountant and a Company Secretary.

Patrick Aghanian is the Chief Executive Officer for European Generics at Dr. Reddy’s Laboratories Limited and a member of Dr. Reddy’s Management Council. Patrick joined Dr. Reddy’s from Zentiva in Prague (Czech Republic). Before becoming Head of Zentiva in 2017, he worked for multinational pharma companies such as Sanofi, GSK, and Novartis, where he held various leadership roles in Eurasia, the Middle East, and Europe.

Patrick earned his Masters of Business Administration from the UCLA Anderson School of Management (USA), and holds a Bachelor of Arts from the University of California, Los Angeles (USA).

Dr. Bruce LA Carter is an independent member of the board at Dr. Reddy’s for the past seven years. He started his long and illustrious career in the biopharma industry at G.D. Searle & Co. In 1986, he joined ZymoGenetics as Vice President of Research and Development and then went on to head the company as Chief Executive Officer from April 1998 to January 2009. During this period, ZymoGenetics was acquired by Novo Nordisk A/S, where he served as Corporate Executive Vice President and Chief Scientific Officer from April 1994 to October 1999.

Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. He has also been a part of academia, as a Lecturer/Professor at Trinity College, University of Dublin, and University of Washington. He received a BSc with Honors in Botany from the University of Nottingham (UK) and a PhD in Microbiology from Queen Elizabeth College, University of London (UK).

Hariharnath Buggana is the Managing Director of InvAscent India – a private equity firm focused on Indian healthcare, pharma, and medtech industries. Prior to this, Hari was a consultant with McKinsey & Company. During his stint at McKinsey, Hari primarily worked with life sciences businesses in the US, Europe, and India on a variety of issues ranging from corporate strategy, mergers and acquisitions, product-market strategy, R&D productivity, organizational effectiveness, and operations improvement.

Prior to joining McKinsey, Hari worked as a scientist in the pharmaceutical products division of Abbott Laboratories (USA). Hari has an MBA from the Kellogg School of Management, Northwestern University and an MS in Chemical Engineering from Illinois Institute of Technology, Chicago (USA).

Prof Shubhada Chiplunkar Former Director of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai and the Head of Cancer Immunology and Immunotherapy Research Group at ACTREC obtained her PhD from University of Mumbai (1983) and post-doctoral fellowship from Max Planck Institute, Freiburg Germany. Her specific expertise is in the areas of cancer immunobiology. She has dedicated over 35 years of research career in understanding immune dysfunctions in the tumor microenvironment of cancer patients. She employed this experience in development of immunotherapeutic strategies for cancer using Gamma Delta T cells. As an adviser within a national consortium on therapeutics, she is involved in guiding the development of cell-based therapeutics, including CART cells and other immunotherapeutic modalities.

She has widely published and continues to actively pursue her scientific interests through diverse platforms. She is the member of several scientific advisory and review committees of national research institutes, DBT, DST, BIRAC, ICMR. She has served as Member of the Board of Governors NIPER- A and Academic Council of Universities and as Senate member of IIT-B. She is the President of Immuno-oncology society of India (IOSI) and Mumbai Immunology Group (MIG). At present she is also the member of the Education Committee of International Union Immunological Societies (IUIS).

Kumar Srinivasan, Ph.D., MBA, in his most recent role served as executive vice president and chief business officer at Turning Point Therapeutics with responsibility for corporate strategy and business development, including collaborations and alliances where he successfully lead the sale of the company to Bristol Myers Squibb for $ 4.1 billion.

Kumar has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice

president and global head of business development for the BioPharmaceutical business unit of AstraZeneca.

During his 9-year tenure at AstraZeneca, Dr. Srinivasan was responsible for all in- and out-licensing, business development and alliance management activities within several therapeutic areas on a regional and global scale. During the pandemic Kumar lead the licensing and global supply agreements for the AstraZeneca’s vaccine and mAb cocktails and contributed significantly to the success of both these programs which made a tremendous impact on global health.

In addition, he previously held executive level business development roles at Wyeth; Vivoryon (formerly known as Probiodrug), a publicly traded biotech based in Germany; and Torrey Pines Therapeutics. Earlier in his career, he held scientific roles at biopharmaceutical companies, Sibia Neurosciences and Genta.

He has a Ph.D from Case Western University in chemistry, did his postdoctoral work at Caltech under Nobel Laureate Professor Frances Arnold and has an MBA with a concentration in finance and strategy from the University of Chicago’s Booth School of Business.